Kymera Therapeutics, Inc.
KYMR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3 | $1 | $1 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $1 | $1 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -40.1% | 67.8% | -35.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -459.4% | -182.2% | -323.9% | -134.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -475.6% | -187% | -330.6% | -137.6% |
| EPS Diluted | -2.98 | -2.52 | -2.87 | -2.09 |
| % Growth | -18.3% | 12.2% | -37.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |